Abstract

BackgroundIn recent decades, arsenic trioxide (ATO) has become a highly promising chemotherapeutic medication for treating APL patients. Owing to its complications, researchers are enthusiastic about applying compounds with fewer side effects. Betulinic acid is a pentacyclic triterpene that is found throughout various plants. ObjectiveDue to the betulinic acid's anti-cancer capabilities, the present investigation aims to look into the betulinic acid's effects on the NB4 cell line. MethodsThe APL cell line (NB4) was cultured with various betulinic acid concentrations. Afterward, the cell viability was appraised via MTT and trypan blue assays. In addition, the apoptosis and Gene expression were assessed using Annexin/7-AAD assay and qRT-PCR, respectively. ResultsAccording to our findings, betulinic acid decreased NB4 cells' viability and metabolic activity in a dose-dependent manner. In comparison to the control group, betulinic acid triggered regulated cell death in NB4 cells. Furthermore, following treatment with 80 g/ml betulinic acid, the hTERT gene's expression decreased by >90%. ConclusionGiven betulinic acid's anti-cancer properties, our findings suggest a viable therapeutic method for treating acute promyelocytic leukemia.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call